Glioma Diagnosis and Treatment

The paper analyzes gene expression in glioblastomas to show endolysosomes in non-tumor cells and immunosuppressive macrophages contribute to a pro-tumorigenic microenvironment.

ClonoScreen3D is a 3D clonogenic screening platform that identifies radiosensitizers for glioblastoma by testing drug-radiation interactions using patient-derived cell lines.

This study compares tumor endothelial cells from low-grade and high-grade gliomas, finding they have distinct molecular profiles and functional roles in regulating tumor growth.

This study identifies RAD18's role in TMZ resistance and hypermutation in GBM by linking it to TLS and MMR pathways through CRISPR screening and mutation analysis.

This paper models glioma oncostreams in vitro, showing their formation, stability, and response to pharmacological agents, with insights into potential anti-invasion targets.

This study evaluates the efficacy of onametostat, a PRMT5 inhibitor, in reducing glioblastoma cell proliferation and viability under normoxic and hypoxic conditions.

The paper develops a machine learning framework to identify RCD-related genes in glioma, identifies SLC43A3 as an oncogenic biomarker, and proposes a gene pair signature for prognosis prediction.

The paper analyzes phenotypic heterogeneity in glioblastoma by examining subtype antagonism in transcriptomic data, finding that the proneural-mesenchymal axis is the dominant antagonistic pair.

The paper characterizes GSC-derived GBM organoids, revealing an immune-like molecular program and identifying SATB2+ and HOPX+ progenitor populations that contribute to GBM progression.

This study uses CRISPRoff to introduce site-specific CpG methylation in the MGMT promoter of glioblastoma cells, showing reduced MGMT expression and increased temozolomide sensitivity.

This study shows that TMZ efficacy in glioblastoma varies with time-of-day due to circadian rhythms in MGMT expression and promoter methylation, with optimal treatment at the peak of Bmal1 expression.

This study shows that EZH2 inhibition synergizes with HDAC inhibitors to kill IDH1R132H mutant glioma cells by reducing H3K27me3 and increasing H3K27ac.

The paper identifies oscillatory genes in glioblastoma, including SOX2, which oscillates in quiescent glioblastoma stem cells, suggesting new regulatory roles in quiescence.

This study shows that brain regions in glioblastoma patients exhibit signs of accelerated ageing similar to Alzheimer's disease, suggesting shared mechanisms of mitochondrial and neuronal dysfunction.

This study shows that ATR inhibition with gartisertib enhances cell death and synergizes with TMZ and RT in glioblastoma cell lines, particularly in TMZ-resistant cells.

This study develops a zebrafish model of glioblastoma driven by specific oncogenic variants and shows inflammation inhibits tumor growth during initiation and relapse.

This study integrates multi-omics data from TCGA to classify glioma types and identify novel biomarkers using DIABLO, finding key pathways and genes associated with glioblastoma and lower-grade gliomas.

This study identifies NQO1 overexpression in PPM1D-truncated DIPG cells and shows that IB-DNQ treatment inhibits tumor growth and extends survival.

The paper develops a cost-effective live-dead staining protocol for monitoring therapy response in spheroid cultures over 10 days using calcein-AM and Helix NP Blue.

The paper uses single-nucleus RNA-sequencing to compare non-enhancing and contrast-enhancing regions of high-grade gliomas, finding distinct cellular states and microenvironment features in NE regions.

This study analyzes the epigenetic evolution of IDH1-mutant and IDH1-wildtype gliomas under treatment, showing IDHmut tumors undergo epigenomic changes resembling IDHwt tumors, with implications for treatment strategies.

This study shows BMP2 and BMP7 work with H3.3K27M to create a quiescent yet invasive state in pediatric gliomas.

This study identifies CD97 as a targetable vulnerability in glioblastoma through its role in tumor metabolism and signaling, supported by transcriptomic, proteomic, and functional analyses.

This study shows that STING activation reduces glioblastoma progression and prolongs survival by altering tumor vasculature and enhancing immune surveillance.

This study shows that BDNF-TrkB signaling promotes malignant synaptic plasticity in gliomas, enhancing tumor progression through mechanisms similar to long-term potentiation in the healthy brain.

This study identifies two molecular phenotypes, ADA and N-ADA, associated with temozolomide resistance in glioblastoma cells through bulk and single-cell RNA sequencing.

This paper develops a deep learning model for intraoperative pediatric CNS tumor classification using rapid sequencing, achieving accurate results within 60-90 minutes.

This study shows rosmarinic acid reduces proliferation and stemness in medulloblastoma cells by targeting HDAC1, EGFR, and ERK signaling, and increasing p21 expression.

OpenPBTA provides a collaborative platform to genomically characterize 1,074 pediatric brain tumors and 22 cell lines, offering analysis modules and somatic datasets for research and clinical applications.

The paper identifies three biomarkers predicting response to NK cell immunotherapy in recurrent GBM using immune profiling and validation techniques.